Larisa Girshova
Saint Petersburg, SPE, Russian Federation
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia: a regional analysis of COMMODORE in China, South-East Asia, and Russia.
Journal: Annals of hematology
Published: October 10, 2024
Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.
Journal: Leukemia
Published: March 18, 2024
Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation.
Journal: Pathophysiology : the official journal of the International Society for Pathophysiology
Published: May 05, 2023
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.
Journal: Blood advances
Published: February 15, 2022
Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study.
Journal: European journal of haematology
Published: October 05, 2021
The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report.
Journal: BMC women's health
Published: November 16, 2020
CASC5 Gene Expression Changes Correlate with Targeted Mutations in Leukemia
Journal: Molekuliarnaia biologiia
Published: February 21, 2020
Showing 1-10 of 10
Last Updated: 09/26/2026